Abstract:ABSTRACT Zoonotic coronaviruses pose a continuous threat to human health, with newly identified bat-borne viruses like swine acute diarrhea syndrome coronavirus (SADS-CoV) causing high mortality in piglets. In vitro studies indicate that SADS-CoV can infect cell lines from diverse species, including humans, highlighting its potential risk to human health. However, the lack of tools to study viral entry, along with the absence of vaccines or antiviral therapies, perpetuates this threat. To address this, we engineered an infectious molecular clone of Vesicular Stomatitis Virus (VSV), replacing its native glycoprotein (G) with SADS-CoV spike (S) and inserting a Venus reporter at the 3′ leader region to generate a replication-competent rVSV-Venus-SADS S virus. Serial passages of rVSV-Venus-SADS S led to the identification of an 11-amino-acid truncation in the cytoplasmic tail of the S protein, which allowed more efficient viral propagation due to increased cell membrane anchoring of the S protein. The S protein was integrated into rVSV-Venus-SADS SΔ11 particles, susceptible to neutralization by sera from SADS-CoV S1 protein-immunized rabbits. Additionally, we found that TMPRSS2 promotes SADS-CoV spike-mediated cell entry. Furthermore, we assessed the serum-neutralizing ability of mice vaccinated with rVSV-Venus-SADS SΔ11 using a prime-boost immunization strategy, revealing effective neutralizing antibodies against SADS-CoV infection. In conclusion, we have developed a safe and practical tool for studying SADS-CoV entry and exploring the potential of a recombinant VSV-vectored SADS-CoV vaccine. IMPORTANCE Zoonotic coronaviruses, like swine acute diarrhea syndrome coronavirus (SADS-CoV), pose a continual threat to human and animal health. To combat this, we engineered a safe and efficient tool by modifying the Vesicular Stomatitis Virus (VSV), creating a replication-competent rVSV-Venus-SADS S virus. Through serial passages, we optimized the virus for enhanced membrane anchoring, a key factor in viral propagation. This modified virus, rVSV-Venus-SADS SΔ11, proved susceptible to neutralization, opening avenues for potential vaccines. Additionally, our study revealed the role of TMPRSS2 in SADS-CoV entry. Mice vaccinated with rVSV-Venus-SADS SΔ11 developed potent neutralizing antibodies against SADS-CoV. In conclusion, our work presents a secure and practical tool for studying SADS-CoV entry and explores the promise of a recombinant VSV-vectored SADS-CoV vaccine.

Evaluation of Attenuated VSVs with Mutated M Or/and G Proteins As Vaccine Vectors

Pathogenicity and Immunogenicity of Recombinant Methyltransferase-Defective Vesicular Stomatitis Virus

Assessment of A Novel Recombinant Vesicular Stomatitis Virus with Triple Mutations in Its Matrix Protein As A Vaccine for Pigs

Construction and Characterization of Recombinant VSV with Double Mutation in M and G Protein

Development of Improved Mumps Vaccine Candidates by Mutating Viral mRNA Cap Methyltransferase Sites in the Large Polymerase Protein

Assessment of Single‐Cycle M‐Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS‐CoV‐2 Immunogen Delivery

Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSV MT ) in golden syrian hamster

Immunogenicity of Mucosal COVID-19 Vaccine Candidates Based on the Highly Attenuated Vesicular Stomatitis Virus Vector (VSVMT) in Golden Syrian Hamster

Safety, efficacy, and DIVA feasibility on a novel live attenuated classical swine fever marker vaccine candidate

Establishment of replication-competent vesicular stomatitis virus recapitulating SADS-CoV entry

Two Point Mutations in the Glycoprotein of SFTSV Enhance the Propagation Recombinant Vesicular Stomatitis Virus Vectors at Assembly Step

Co-expressing GP5 and M Proteins under Different Promoters in Recombinant Modified Vaccinia Virus Ankara (Rmva)-Based Vaccine Vector Enhanced the Humoral and Cellular Immune Responses of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)

Preliminary Evaluation of Protective Efficacy of Inactivated Senecavirus A on Pigs

Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector

Recombinant vesicular stomatitis virus expressing the spike protein of genotype 2b porcine epidemic diarrhea virus: A platform for vaccine development against emerging epidemic isolates

Potent Protective Immune Responses to Senecavirus Induced by Virus-Like Particle Vaccine in Pigs

Porcine Monocyte-Derived Dendritic Cells Can Be Differentially Activated by Vesicular Stomatitis Virus and Its Matrix Protein Mutants.

Vesicular stomatitis virus glycoprotein suppresses nuclear factor kappa-B- and mitogen-activated protein kinase-mediated pro-inflammatory responses dependent on sialic acids

A Novel Replication-Competent Vaccinia Vector MVTT is Superior to MVA for Inducing High Levels of Neutralizing Antibody Via Mucosal Vaccination

Complementation of a vesicular stomatitis virus glycoprotein G mutant with wild-type protein expressed from either a bovine papilloma virus or a vaccinia virus vector system

Development and evaluation of inactivated vaccines incorporating a novel Senecavirus A strain-based Immunogen and various adjuvants in mice